Table 2

Family-based associations between CYP3A4 and CYP3A5 genotypes and risk of prostate cancer among cases and sibling controls

GenotypeOR (95% CIs), Pa
No stratificationStratified by disease aggressivenessb
LowHigh
CYP3A4
 *1A/*1A1.0 (referent)1.01.0
 All Subjects*1A/*1B or *1B/*1B0.76 (0.48–1.20), 0.240.20 (0.07–0.60), 0.0041.32 (0.77–2.27), 0.31
 Caucasians*1A/*1B or *1B/*1B0.83 (0.48–1.42), 0.490.08 (0.01–0.49), 0.0061.91 (1.02–3.57), 0.04
 African-Americans*1A/*1B or *1B/*1B0.61 (0.27–1.36), 0.230.66 (0.16–2.65), 0.560.49 (0.17–1.43), 0.19
CYP3A5
 *3/*31.0 (referent)1.01.0
 All Subjects*3/*1 or *1/*10.73 (0.51–1.05), 0.090.45 (0.25–0.82), 0.0091.10 (0.68–1.77), 0.69
 Caucasians*3/*1 or *1/*10.71 (0.49–1.04), 0.080.42 (0.22–0.78), 0.0061.16 (0.70–1.91), 0.56
 African-Americans*3/*1 or *1/*11.00 (0.29–3.52), 1.000.92 (0.10–8.69), 0.940.70 (0.08–5.75), 0.74
  • a Adjusted for age.

  • b Cases and their brothers stratified by tumor aggressiveness of affected brother. Low aggressiveness: Gleason <7, and T category <T2c. High aggressiveness: Gleason ≥7, or T category ≥T2c.